2
Jul
2019
Cancer Survivor and Cancer Drug Developer: Laura Shawver on The Long Run
Today’s guest on The Long Run is Laura Shawver. Laura is the CEO of San Diego-based Synthorx. This company, based on research from The Scripps Research Institute, is using a couple of newly invented base pairs of DNA to make site-specific modifications on fully expressed proteins. This capability, Synthorx believes, could be put to practical use to craft ideal drug-like...Read More 
Share:
1
Jul
2019
Has the Time Come for a US NICE?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
27
Jun
2019
AbbVie & Allergan (Groan), Adaptive Headlines IPO Rush, & FDA Cops on the Beat
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
24
Jun
2019
Just Because You Can Doesn’t Mean You Should: Gene Therapy is Not the Solution to Every Problem
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
20
Jun
2019
Pfizer’s Wager on Small Molecules, Summer IPO Flurries, Gilead’s Protein Degrader Play
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
13
Jun
2019
Who Will Be the Next Celgene of Dealmaking?
Stars aligned beautifully, not long ago, for dealmaking at Celgene. The company, early this decade, was raking in the dough from the multiple myeloma drug Revlimid. Cash had to be spent somewhere. Celgene didn’t have much of its own R&D. Shareholders weren’t clamoring for their cut, via quarterly cash dividends. The stock soared, without any jet fueled-share buybacks. Letting cash...Read More
Share:
13
Jun
2019
Predicting Who Will Benefit from Cancer Drugs: Liz O’Day on The Long Run
Today’s guest on The Long Run is Liz O’Day. Liz is the founder and CEO of Cambridge, Mass.-based Olaris Therapeutics. This is a scrappy little startup that’s studying metabolites that could provide clues for predicting which patients are most likely to respond to certain cancer drugs. Figuring out which patients are likely to respond is one of those perennial challenges...Read More
Share:
31
May
2019
Organs-on-a-chip, Organoids Start to Deliver Results as an Alternative Preclinical Route
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
30
May
2019
Third Rock and Friends Bet $110M On Thrive, a Hopkins-Inspired Cancer Screening Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
28
May
2019
Baseball Comes to Surprise Medical Billing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
22
May
2019
From Open Biology to Pharma Leadership: Jay Bradner of Novartis on The Long Run
Today’s guest on The Long Run is Jay Bradner. Jay is the president of the Novartis Institutes for Biomedical Research (NIBR). This is one of the heavyweight organizations in Big Pharma industry R&D. When Novartis planted this operation in the heart of Cambridge, Mass. more than a decade ago, it was the start of a trend toward Big Pharma R&D...Read More
Share:
20
May
2019
Pain Drug Development Flounders in the Opioid Crisis, but Novel Mechanisms Emerging
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
16
May
2019
Amgen Swings for the RAS Fence, Gilead’s Grilling on Price, & Agios Enlarges the Pie
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
13
May
2019
LivLyme and the Many Hats of Patient Advocacy Organizations
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
8
May
2019
An Elephant for Immunology Drugs: Sheila Gujrathi on The Long Run
Today’s guest on The Long Run is Sheila Gujrathi. Sheila is the CEO of San Diego-based Gossamer Bio. This immunology drug developer is an example of what I’ve lately started calling an “elephant” startup (see February TR coverage of Maze Therapeutics for another example). Gossamer was co-founded by Sheila and Faheem Hasnain. They were the dynamic duo that led Receptos...Read More
Share:
8
May
2019
Thank You, Biotech: Kili Climb to Fight Has Crushed Its $1m Goal for Cancer Research
Today, I want to say thank you. Thank you to the biotech community for your Incredibly Generous support of the Kilimanjaro Climb to Fight Cancer. You have enabled us to reach our goal of raising $1 million this year for lifesaving cancer research at Fred Hutch. Who are we? We are a team of 28 biotech executives and investors. 14...Read More
Share:
6
May
2019
Investing from the Heart to Find New ALS Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
29
Apr
2019
Membraneless Organelles Offer New Drug Discovery Opportunities
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
23
Apr
2019
Blazing a New Trail in Psychiatry & Women’s Health: Jeff Jonas on The Long Run
Today’s guest on The Long Run is Jeff Jonas. Jeff is the CEO of Cambridge, Mass.-based Sage Therapeutics. The company made big news – front page of the New York Times – a month ago. That’s when it won FDA clearance to sell the first drug ever for postpartum depression. It’s a big story for a number of reasons. Postpartum...Read More
Share:
23
Apr
2019
3 Lessons for Success in Research: Reflections from AACR 2019
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share: